Skip to main content
Equibles
PHAT logo

PHAT · Phathom Pharmaceuticals, Inc. · Earnings Call Transcripts & Audio

Track PHAT — free

Use PHAT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PHAT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.36 -0.01 (-0.12%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$676.33M
Shares
80.90M

Phathom Pharmaceuticals, Inc. Earnings Call Transcripts

Quarterly earnings calls for Phathom Pharmaceuticals, Inc. (PHAT), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $682,000 −$79.57M '23 Q4 24-03-07 · $1.91M −$82.85M '24 Q1 24-05-09 · $7.32M −$91.45M '24 Q2 24-08-08 · $16.35M −$85.58M '24 Q3 24-11-07 ▲4249.6% $29.66M −$74.45M '24 Q4 25-03-06 ▲1391.6% $28.52M −$94.32M '25 Q1 25-05-01 ▲439.4% $39.50M −$75.81M '25 Q2 25-08-07 ▲202.7% $49.50M −$29.97M '25 Q3 25-10-30 ▲94.1% $57.58M −$21.15M '25 Q4 26-02-26 ▲104.4% $58.30M −$30.37M '26 Q1 26-04-30 LATEST ▲88% $74.27M −$17.58M '26 Q2 26-07-30
Earnings call
FY26 · Q2
2026-07-30
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript
Confident tone Voquesna prescription metrics Physician access friction for Voquesna Revenue growth and profitability inflection
Revenue
$74.27M
▲ 88% YoY
Diluted EPS
$-0.21
Gross margin
79.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Phathom Pharmaceuticals, Inc. (PHAT) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Phathom Pharmaceuticals, Inc. (PHAT) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-30
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
Confident tone New-to-Brand Prescription Share (NBRX) Gastroenterology Strategy Execution Total Prescription (TRX) and Refill Persistence
Revenue
$58.30M
▲ 104.4% YoY
Diluted EPS
$-0.37
Gross margin
79.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-15
Phathom Pharmaceuticals, Inc. (PHAT) April 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-26
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript
Confident tone Revenue performance and 2026 guidance Vaquesna commercial uptake Gross-to-net and seasonality
Revenue
$57.58M*
▲ 94.1% YoY
Gross margin
86.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript
Confident tone Sales Force Realignment Prescription Metrics Gastroenterology Strategic Shift
Revenue
$49.50M
▲ 202.7% YoY
Diluted EPS
$-0.41
Gross margin
87.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call Transcript
Confident tone Sales force realignment toward gastroenterologists Eosinophilic esophagitis (EoE) development BlinkRx cash pay channel and access
Revenue
$39.50M
▲ 439.4% YoY
Diluted EPS
$-1.05
Gross margin
87.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript
Positive tone Citizens Petition and exclusivity timeline VOQUEZNA commercial launch and revenue growth Manufacturing and tariffs
Revenue
$28.52M
▲ 1391.6% YoY
Diluted EPS
$-1.31
Gross margin
86.9%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript
Confident tone VOQUEZNA commercial launch and growth momentum Non-Erosive GERD approval inflection Eosinophilic esophagitis (EoE) label expansion
Revenue
$29.66M*
▲ 4249.6% YoY
Gross margin
87.1%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript
Confident tone VOQUEZNA commercial launch momentum Guidance visibility for 2025 Non-Erosive GERD label expansion
Revenue
$16.35M
Diluted EPS
$-1.32
Gross margin
85.6%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript
Confident tone VOQUEZNA launch momentum Patient testimonials and demand Physician adoption / prescriber mix
Revenue
$7.32M
Diluted EPS
$-1.56
Gross margin
81.2%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript
Confident tone BlinkRx reliance and cash-pay dynamics Nonerosive GERD label expansion opportunity Direct-to-consumer marketing campaign
Revenue
$1.91M
Diluted EPS
$-1.42
Gross margin
77.7%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-07
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript
Confident tone VOQUEZNA launch progress Launch variability and risk Demand versus filled prescriptions
Revenue
$682,000*
Gross margin
75.5%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–15 of 15 earnings calls
Key facts CIK 1783183 CUSIP 71722W107 13F (30d) 64 filings 64 filers Visit website Investor relations